Eupraxia Pharmaceuticals Inc (EPRX) Return on Investment ROI from the fourth quarter of 2025 to fourth quarter of 2024 and for the year 2025, average high and low, overall ranking from Dec 31 2025 to Dec 31 2024 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Eupraxia Pharmaceuticals Inc   (NASDAQ: EPRX)


Eupraxia Pharmaceuticals Inc's ROI from its fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Eupraxia Pharmaceuticals Inc's ROI in the fourth quarter of 2025?
Eupraxia Pharmaceuticals Inc recorded a cumulative net loss of $-39 million during 12 months ending in the fourth quarter of 2025, resulting in a negative return on investment (ROI) of -48.66%.

Within the Healthcare sector 570 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the third quarter of 2025 from 4035 to 4332.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Dec 31 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2024)
IV. Quarter
Y / Y Investment Change TTM 134.97 % 172.2 % 175.48 % 270.69 % 779.99 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 81 79 79 79 35
Return On Investment (TTM) -48.66 % -37.9 % -45.53 % -57.01 % -76.24 %
EPRX's Overall Ranking # 4332 # 4035 # # #
Seq. Investment Change TTM 16.8 % 20.14 % 25.22 % 33.72 % 35.31 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -39 -26 -26 -26 -26

EPRX Company Profile >> Back to EPRX Roi Comparisons >> See Annual EPRX Return On Investment



Return On Investment EPRX's Ranking
Within: No.
Industry # 241
Sector # 571
Overall # 4332

Return On Investment Statistics
High Average Low
-47.94 %
-60.81 %
-73.68 %
(Dec 31 2025)   (Dec 31 2024)







Financial Statements
Eupraxia Pharmaceuticals Inc's IV. Quarter Investments $ 81 Millions EPRX's Balance sheet
Eupraxia Pharmaceuticals Inc's IV. Quarter Income $ -39 Millions Quarterly EPRX's Income Statement
EPRX's Income by Division See EPRX's Income by Division


EPRX Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2022)
2023

Total Investments in Millions 81 35 8 0 0
Y / Y Investment Growth 130.44 % 314.21 % - - -
Net Income in Millions -39 -26 -29 0 0
Y / Y Net Income Growth - - - - -
Annual Return On Investment -47.94 % -73.68 % -343.37 % - -


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
EPRX's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for EPRX's Competitors
Subscribers only: Roi for Eupraxia Pharmaceuticals Inc's Suppliers
Subscribers only: Return On Investment for EPRX's Customers

Other Ratios
EPRX's Roa EPRX's Inventory Turnover Ratio EPRX's Growth Rates EPRX's Dividend Statistics
EPRX's Profitability Ratios EPRX's Asset Turnover Ratio EPRX's Dividend Growth
EPRX's Roe EPRX's Valuation Ratios EPRX's Financial Strength Ratios EPRX's Dividend Payout Ratio



Companies with similar Return On Investment at Dec 31 2025, within Healthcare Sector ROI

Date modified: 2026-07-07T10:40:17+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.